Recent advances in CSF biomarkers for Parkinson's disease

Parkinsonism and Related Disorders

Volumn 18, Issue SUPPL. 1, 2012, Pages

  LeWitt, Peter ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Cerebrospinal fluid (CSF); Homovanillic acid; Metabolomics; Parkinson's disease; Proteo mics; Xanthine

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALPHA SYNUCLEIN; AMINO ACID ACETYLTRANSFERASE; AMYLOID BETA PROTEIN[1-42]; BETAINE; BIOLOGICAL MARKER; CORTICOSTERONE; CYCLO(LEUCYLPROLINE); CYCLOPEPTIDE; DJ 1 PROTEIN; FRACTALKINE; GLUTATHIONE DISULFIDE; HOMOVANILLIC ACID; OSTEOPONTIN; PHOSPHOPROTEIN; PIPECOLIC ACID; SUCCINYLCARNITINE; TAU PROTEIN; UNCLASSIFIED DRUG; URATE; XANTHINE; AMYLOID BETA PROTEIN; CD135 ANTIGEN; NEUROTRANSMITTER; PROTEIN; PROTEIN DEGLYCASE DJ-1;

ARTICLE; AUTONOMIC DENERVATION; CEREBROSPINAL FLUID; CORPUS STRIATUM; DISEASE COURSE; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; LEWY BODY; MASS FRAGMENTOGRAPHY; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SHY DRAGER SYNDROME; SYNUCLEINOPATHY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; CEREBROSPINAL FLUID ANALYSIS; DOPAMINE METABOLISM; EXTRACELLULAR FLUID; METABOLOMICS; STUDENT T TEST;

EID: 84858641747     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/s1353-8020(11)70017-7     Document Type: Article

References (18)

1. LeWitt PA, Galloway MP. Neurochemical markers of Parkinson's disease. In: Koller WC, Paulson G, editors. Therapy of Parkinson's disease. New York: Marcel Dekker; 1990, pp. 63-93.
2. LeWitt P, Galloway M, Matson W, Milbury P, McDermott M, Srivastava DK, et al. Markers of dopamine metabolism in Parkinson's disease. Neurology 1992;42: 2111-7.
3. Goldstein DS, Holmes C, Bentho O, Sato T, Moak J, Sharabi Y, et al. Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord 2008;14:600-7.
4. Parkinson Study Group. CSF homovanillic acid in the DATATOP study on Parkinson's disease. Arch Neurol 1995;52:237-45.
5. Loeffler DA, LeWitt PA, Juneau PL, Camp DM, Dimaggio AJ, Milbury P, et al. Altered guanosine and guanine concentrations in rabbit striatum following increased dopamine turnover. Brain Res Bull 1998;45:297-9.
6. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, et al. Urate as a predictor of the slower rate of clinical decline in Parkinson disease. Arch Neurol 2009;66:1460-8.
7. Niklasson F, Ågren H, Hällgren R. Purine and monoamine metabolites in cerebrospinal fluid: parallel purinergic and monoaminergic activation in depressive illness? J Neurol Neurosurg Psychiatr 1983;46:255-60.
8. LeWitt PA, Schultz L, Auinger P, Lu M, Parkinson Study Group-DATATOP Study Investigators. CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease. Brain Res 2011;1408:88-97.
9. LeWitt PA, Lu M, Poisson L, Beach T, Adler C, Guo L. PD biomarker search: metabolomic analysis of post-mortem CSF. Mov Disord 2011;26(Suppl 2):S193.
10. Isobe C, Abe T, Terayama Y. Levels of reduced and oxidized coenzyme Q-10 and 8'-hydroxy-2'-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. Neurosci Lett 2010;469:159-63.
11. Boll MC, Caraz-Zubeldia M, Montes S, Rios C. Free copper, ferroxidase and SOD1 activities, lipid peroxidation, and NO(x) content in the CSF: a different marker profile in four neurodegenerative diseases. Neurochem Res 2008;33:1717-23.
12. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG. a-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011; 10:230-40.
13. Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, Qureshi MM, et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006;349: 162-6.
14. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, et al. DJ-1 and alphasynuclein in humans cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010;133:713-26.
15. Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011;69:570-80.
16. Abdo WF, Bloem BR, van Geel WJ, Esselink RA, Verbeek MM. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol Aging 2007;28:742-47.
17. Maetzler W, Berg D, Schalamberidze N, Melms A, Schott K, Mueller JC, et al. Osteopontin is elevated in parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol Dis 2007;25:473-82.
18. Sherer TB. Biomarkers for Parkinson's disease. Sci Transl Med 2011;3:79ps14.